The Chemistry Behind ADCs.

Published on May 7, 2021in Pharmaceuticals4.286
· DOI :10.3390/PH14050442
Kostova Vesela , Desos Patrice + 1 AuthorsAndrás Kotschy19
Estimated H-index: 19
Combining the selective targeting of tumor cells through antigen-directed recognition and potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in recent years as an efficient therapeutic approach for the treatment of various cancers. Besides a number of approved drugs already on the market, there is a formidable follow-up of ADC candidates in clinical development. While selection of the appropriate antibody (A) and drug payload (D) is dictated by the pharmacology of the targeted disease, one has a broader choice of the conjugating linker (C). In the present paper, we review the chemistry of ADCs with a particular emphasis on the medicinal chemistry perspective, focusing on the chemical methods that enable the efficient assembly of the ADC from its three components and the controlled release of the drug payload.
#1Angeliki Andrikopoulou (Alexandra Hospital)H-Index: 2
#2Eleni Zografos (Alexandra Hospital)H-Index: 2
Last. Flora Zagouri (Alexandra Hospital)H-Index: 29
view all 6 authors...
The development of antibody-drug conjugates composed of a cytotoxic agent and a monoclonal antibody carrier offers an important alternative to classic chemotherapy strategies. Trastuzumab deruxtecan (DS-8201a) is a next-generation antibody-drug conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, an exatecan derivative (DX-8951f). DS-8201a resulted in favorable outcomes in HER2-positive heavily pretreated breast cancer patients and also had a promising efficacy ...
7 CitationsSource
#1Joshua Z. Drago (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#2Shanu Modi (Cornell University)H-Index: 46
Last. Sarat Chandarlapaty (Cornell University)H-Index: 51
view all 3 authors...
Nine different antibody–drug conjugates (ADCs) are currently approved as cancer treatments, with dozens more in preclinical and clinical development. The primary goal of ADCs is to improve the therapeutic index of antineoplastic agents by restricting their systemic delivery to cells that express the target antigen of interest. Advances in synthetic biochemistry have ushered in a new generation of ADCs, which promise to improve upon the tissue specificity and cytotoxicity of their predecessors. M...
37 CitationsSource
#1Eugen MerkulH-Index: 15
#2Joey A. MunsH-Index: 5
Last. Guus A.M.S. van DongenH-Index: 64
view all 8 authors...
The Pt(II)-linker [ethylenediamineplatinum(II)] 2+ , coined "Lx" ® , has emerged as a novel non-conventional approach to antibody-drug conjugates (ADCs) and has shown its potential in preclinical in vitro and in vivo benchmark studies. A crucial improvement of the Lx -conjugation reaction from initially <15% to ~75-90% conjugation efficiency is described, resulting from a systematic screening of all relevant reaction parameters. The main unexpected and counterintuitive finding was that NaI, a st...
5 CitationsSource
#1Stephen J. Walsh (University of Cambridge)H-Index: 9
#2Jonathan D. Bargh (University of Cambridge)H-Index: 4
Last. David R. Spring (University of Cambridge)H-Index: 63
view all 14 authors...
Antibody-drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. They have garnered widespread interest in drug discovery, particularly in oncology, as discrimination between healthy and malignant tissues or cells can be achieved. Nine ADCs have received approval from the US Food and Drug Administration and more than 80 others are currently undergoing clinical investigations for a range of solid tumours and h...
26 CitationsSource
#1Zhi‐Yan Guo (USTC: University of Science and Technology of China)H-Index: 4
#2Chen-Xuan Li (USTC: University of Science and Technology of China)H-Index: 8
Last. Wen-Wei Li (USTC: University of Science and Technology of China)H-Index: 57
view all 7 authors...
212 CitationsSource
#1Rafael Hartmann (Uppsala University)H-Index: 2
#2Raphael FahrnerH-Index: 1
Last. Luke R. Odell (Uppsala University)H-Index: 23
view all 7 authors...
Auristatins are a class of ultrapotent microtubule inhibitors, whose growing clinical popularity in oncology is based upon their use as payloads in antibody-drug conjugates (ADCs). The most widely utilized auristatin, MMAE, has however been shown to cause apoptosis in non-pathological cells proximal to the tumour ("bystander killing"). Herein, we introduce azastatins, a new class of auristatin derivatives encompassing a side chain amine for antibody conjugation. The synthesis of Cbz-azastatin me...
1 CitationsSource
#1Elaheh Khozeimeh Sarbisheh (U of S: University of Saskatchewan)H-Index: 6
#2Guillaume Dewaele-Le Roi (CUNY: City University of New York)H-Index: 3
Last. Eric W. Price (U of S: University of Saskatchewan)H-Index: 13
view all 7 authors...
Chemoselective reactions with thiols have long held promise for the site-specific bioconjugation of antibodies and antibody fragments. Yet bifunctional probes bearing monovalent maleimides-long the "gold standard" for thiol-based ligations-are hampered by two intrinsic issues: the in vivo instability of the maleimide-thiol bond and the need to permanently disrupt disulfide linkages in order to facilitate bioconjugation. Herein, we present the synthesis, characterization, and validation of DiPODS...
2 CitationsSource
#1Nicolas Joubert (François Rabelais University)H-Index: 15
#2Alain BeckH-Index: 56
Last. Caroline Denevault-Sabourin (François Rabelais University)H-Index: 6
view all 4 authors...
An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and...
47 CitationsSource
#1Heng ChengH-Index: 1
#2Qiang CongH-Index: 2
Last. Sanjeev Gangwar (BMS: Bristol-Myers Squibb)H-Index: 9
view all 23 authors...
Antibody-drug conjugates (ADCs) use antibodies to deliver cytotoxic payloads directly into tumor cells via specifically binding to the target cell surface antigens. ADCs can enhance the antitumor e...
1 CitationsSource
#1Mary J. O’Sullivan (UCC: University College Cork)H-Index: 1
#2Andrew J. Lindsay (UCC: University College Cork)H-Index: 16
The endosomal recycling pathway lies at the heart of the membrane trafficking machinery in the cell. It plays a central role in determining the composition of the plasma membrane and is thus critical for normal cellular homeostasis. However, defective endosomal recycling has been linked to a wide range of diseases, including cancer and some of the most common neurological disorders. It is also frequently subverted by many diverse human pathogens in order to successfully infect cells. Despite its...
9 CitationsSource
Cited By4
Protease-activated prodrugs leverage the increased activity of proteases in the tumor microenvironment and the tight regulation in healthy tissues to provide selective activation of cytotoxins in the tumor while minimizing toxicity to normal tissues. One of the largest classes of protease-activated prodrugs are composed of therapeutic agents conjugated to macromolecular carriers via peptide motifs that are substrates for cathepsin B, and antibody-drug conjugates are one of the most successful de...
#1Juliana T. W. TongH-Index: 1
#2Paul W. R. HarrisH-Index: 18
Last. Iman KavianiniaH-Index: 9
view all 4 authors...
The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemi...
#2Alberto Ocaña (Symphogen)
Last. Atanasio PandiellaH-Index: 63
view all 3 authors...
In the last 20 years, antibody-drug conjugates (ADCs) have been incorporated into the oncology clinic as treatments for several types of cancer. So far, the Food and Drug Administration (FDA) has approved 11 ADCs and other ADCs are in the late stages of clinical development. Despite the efficacy of this type of drug, the tumors of some patients may result in resistance to ADCs. Due to this, it is essential not only to comprehend resistance mechanisms but also to develop strategies to overcome re...
#2Andrew W.B. Craig (Queen's University)H-Index: 27
Last. Jeffrey V. Leyton (Centre Hospitalier Universitaire de Sherbrooke)H-Index: 6
view all 3 authors...
Biologically-based therapies increasingly rely on the endocytic cycle of internalization and exocytosis of target receptors for cancer therapies. However, receptor trafficking pathways (endosomal sorting (recycling, lysosome localization) and lateral membrane movement) are often dysfunctional in cancer. Antibody-drug conjugates (ADCs) have revitalized the concept of targeted chemotherapy by coupling inhibitory antibodies to cytotoxic payloads. Significant advances in ADC technology and format, a...